The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis - PubMed (original) (raw)
. 2005 Oct 21;123(2):207-18.
doi: 10.1016/j.cell.2005.09.025.
Affiliations
- PMID: 16239140
- DOI: 10.1016/j.cell.2005.09.025
Free article
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis
Akihiko Yokoyama et al. Cell. 2005.
Free article
Abstract
The Mixed-Lineage Leukemia (MLL) protein is a histone methyltransferase that is mutated in clinically and biologically distinctive subsets of acute leukemia. MLL normally associates with a cohort of highly conserved cofactors to form a macromolecular complex that includes menin, a product of the MEN1 tumor suppressor gene, which is mutated in heritable and sporadic endocrine tumors. We demonstrate here that oncogenic MLL fusion proteins retain an ability to stably associate with menin through a high-affinity, amino-terminal, conserved binding motif and that this interaction is required for the initiation of MLL-mediated leukemogenesis. Furthermore, menin is essential for maintenance of MLL-associated but not other oncogene induced myeloid transformation. Acute genetic ablation of menin reverses aberrant Hox gene expression mediated by MLL-menin promoter-associated complexes, and specifically abrogates the differentiation arrest and oncogenic properties of MLL-transformed leukemic blasts. These results demonstrate that a human oncoprotein is critically dependent on direct physical interaction with a tumor suppressor protein for its oncogenic activity, validate a potential target for molecular therapy, and suggest central roles for menin in altered epigenetic functions underlying the pathogenesis of hematopoietic cancers.
Similar articles
- Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
Yokoyama A, Cleary ML. Yokoyama A, et al. Cancer Cell. 2008 Jul 8;14(1):36-46. doi: 10.1016/j.ccr.2008.05.003. Cancer Cell. 2008. PMID: 18598942 Free PMC article. - Interaction of MLL amino terminal sequences with menin is required for transformation.
Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Caslini C, et al. Cancer Res. 2007 Aug 1;67(15):7275-83. doi: 10.1158/0008-5472.CAN-06-2369. Cancer Res. 2007. PMID: 17671196 Free PMC article. - Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.
Murai MJ, Chruszcz M, Reddy G, Grembecka J, Cierpicki T. Murai MJ, et al. J Biol Chem. 2011 Sep 9;286(36):31742-8. doi: 10.1074/jbc.M111.258186. Epub 2011 Jul 13. J Biol Chem. 2011. PMID: 21757704 Free PMC article. - Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation.
Dreijerink KM, Höppener JW, Timmers HM, Lips CJ. Dreijerink KM, et al. Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):562-70. doi: 10.1038/ncpendmet0292. Nat Clin Pract Endocrinol Metab. 2006. PMID: 17024155 Review. - Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
Lei H, Zhang SQ, Fan S, Bai HR, Zhao HY, Mao S, Xin M. Lei H, et al. J Med Chem. 2021 Nov 11;64(21):15519-15533. doi: 10.1021/acs.jmedchem.1c00872. Epub 2021 Nov 2. J Med Chem. 2021. PMID: 34726905 Review.
Cited by
- A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
Soto-Feliciano YM, Sánchez-Rivera FJ, Perner F, Barrows DW, Kastenhuber ER, Ho YJ, Carroll T, Xiong Y, Anand D, Soshnev AA, Gates L, Beytagh MC, Cheon D, Gu S, Liu XS, Krivtsov AV, Meneses M, de Stanchina E, Stone RM, Armstrong SA, Lowe SW, Allis CD. Soto-Feliciano YM, et al. Cancer Discov. 2023 Jan 9;13(1):146-169. doi: 10.1158/2159-8290.CD-22-0416. Cancer Discov. 2023. PMID: 36264143 Free PMC article. - Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor.
Ezoe S. Ezoe S. Int J Environ Res Public Health. 2012 Jul;9(7):2444-53. doi: 10.3390/ijerph9072444. Epub 2012 Jul 10. Int J Environ Res Public Health. 2012. PMID: 22851953 Free PMC article. Review. - Epigenetic Control of Infant B Cell Precursor Acute Lymphoblastic Leukemia.
de Barrios O, Parra M. de Barrios O, et al. Int J Mol Sci. 2021 Mar 18;22(6):3127. doi: 10.3390/ijms22063127. Int J Mol Sci. 2021. PMID: 33803872 Free PMC article. Review. - HSP27/Menin Expression as New Prognostic Serum Biomarkers of Prostate Cancer Aggressiveness Independent of PSA.
Bourefis A, Berredjem H, Djeffal O, Le TK, Giusiano S, Rocchi P. Bourefis A, et al. Cancers (Basel). 2022 Sep 29;14(19):4773. doi: 10.3390/cancers14194773. Cancers (Basel). 2022. PMID: 36230697 Free PMC article. - Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM, Steiner M, Rausch J, Sasca D, Schönfeld J, Kunz K, Taubert MC, McGeehan GM, Chen CW, Mupo A, Hähnel P, Theobald M, Kindler T, Koche RP, Vassiliou GS, Armstrong SA, Kühn MWM. Dzama MM, et al. Blood. 2020 Nov 19;136(21):2442-2456. doi: 10.1182/blood.2020005037. Blood. 2020. PMID: 32589720 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources